Many innovations in biotechnology are derivatives of a naturally occurring biological process. RNAi and the CRISPR-Cas 9 system are both contemporary examples of this.  These techniques offer clear advantages with respect to basic research, the potential to treat disease, and the ability to edit genes with great accuracy. With technology, however, comes responsibility. Just because you can do something, in vitro or in vivo, doesn't always mean that you should do it.So where do you draw the line?

Drawing the line in the use of biotechnology innovations like RNAi and the CRISPR-Cas 9 system is a complex issue that involves ethical, legal, and societal considerations. Here are some steps to consider:

1. Ethical Considerations: The first step is to consider the ethical implications of the technology. This includes considering the potential harm and benefits to individuals and society. For example, gene editing could potentially cure genetic diseases, but it could also be used for non-therapeutic enhancements that could lead to social inequality.

2. Legal Considerations: The next step is to consider the legal framework in which the technology is being used. This includes national and international laws and regulations. For instance, some countries have strict regulations on the use of gene editing in humans, while others have more lenient rules.

3. Societal Considerations: The final step is to consider societal attitudes and beliefs about the technology. This includes public opinion, religious beliefs, and cultural values. For example, some societies may be more accepting of gene editing than others.

In conclusion, drawing the line in the use of biotechnology innovations is not a straightforward task. It requires a careful balance of ethical, legal, and societal considerations. It's not just about what we can do, but also about what we should do.